ABC | Volume 113, Nº1, July 2019

Original Article Kızıltunç et al. Sirtuins in acute myocardial infarction patients Arq Bras Cardiol. 2019; 113(1):33-39 This is an open-access article distributed under the terms of the Creative Commons Attribution License 22. Miranda MX, van Tits LJ, Lohmann C, Arsiwala T, Winnik S, Tailleux A, et al. The Sirt1 activator SRT3025 provides atheroprotection in Apoe-/- mice by reducing hepatic Pcsk9 secretion and enhancing Ldlr expression. Eur Heart J. 2015;36(1):51-9. 23. Stavrou EX, Fang C, Merkulova A, Alhalabi O, Grobe N, Antoniak S, et al. Reduced thrombosis in Klkb1-/- mice is mediated by increased Mas receptor, prostacyclin, Sirt1, and KLF4 and decreased tissue factor. Blood. 2015;125(4):710-9. 24. Tao R, ColemanMC, Pennington JD, OzdenO, Park SH, Jiang H, et al. Sirt3- mediated deacetylation of evolutionarily conserved lysine 122 regulates MnSOD activity in response to stress. Mol Cell. 2010;40(6):893-904. 25. Sundaresan NR, GuptaM, KimG, Rajamohan SB, Isbatan A, GuptaMP. Sirt3 blocksthecardiachypertrophicresponsebyaugmentingFoxo3a-dependent antioxidantdefensemechanisms inmice.JClinInvest.2009;119(9):2758-71. 26. LappasM. Anti-inflammatory properties of sirtuin 6 in human umbilical vein endothelial cells. Mediators Inflamm. 2012 Oct;2012:597514. 27. Tao R, Xiong X, Depinho RA, Deng CX, Dong XC. FoxO3 transcription factor and Sirt6 deacetylase regulate low density lipoprotein (LDL)-cholesterol homeostasis via control of the proprotein convertase subtilisin/kexin type 9 (Pcsk9) gene expression. J Biol Chem. 2013;288(41):29252-9. 28. Gorenne I, Kumar S, Gray K, Figg N, Yu H, Mercer J, et al. Vascular smooth muscle cell sirtuin 1 protects against DNA damage and inhibits atherosclerosis. Circulation. 2013;127(3):386-96. 29. Breitenstein A, Wyss CA, Spescha RD, Franzeck FC, Hof D, Riwanto M, et al. Peripheral blood monocyte Sirt1 expression is reduced in patients with coronary artery disease. PLoS One. 2013;8(1):e53106. 30. Kilic U, Gok O, Bacaksiz A, Izmirli M, Elibol-Can B, Uysal O. SIRT1 gene polymorphismsaffecttheproteinexpression incardiovasculardiseases.PLoS One. 2014;9(2):e90428. 31. Vachharajani VT, Liu T, Wang X, Hoth JJ, Yoza BK, Mccall CE. Sirtuins Link Inflammation and Metabolism. J Immunol Res. 2016 Dec;2016:8167273. 32. Galli M, Van Gool F, Leo O. Sirtuins and inflammation: Friends or foes?. Biochem Pharmacol. 2011;81(5):569-76. 33. Kloner RA. Does reperfusion injury exist in humans? J Am Coll Cardiol. 1993;21(2):537-45. 34. CannonRO.Mechanisms,managementand futuredirections forreperfusion injury after acute myocardial infarction. Nat Clin Pract Cardiovasc Med. 2005;2(2):88-94. 35. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation. 1986;74(5):1124-36. 36. HeuschG.Molecularbasisofcardioprotection:signaltransductioninischemic pre-, post-, and remote conditioning. Circ Res. 2015;116(4):674-99. 37. Feng J, Yang Y, Zhou Y, Wang B, Xiong H, Fan C, et al. Bakuchiol attenuates myocardialischemiareperfusioninjurybymaintainingmitochondrialfunction: the role of silent information regulator 1. Apoptosis. 2016;21(5):532-45. 38. Hafner AV, Dai J, Gomes AP, Xiao CY, Palmeira CM, Rosenzweig A, et al. Regulation of the mPTP by SIRT3-mediated deacetylation of CypD at lysine 166 suppresses age-related cardiac hypertrophy. Aging (Albany NY). 2010;2(12):914-23. 39. Kiziltunc E, Abaci A, Ozkan S, Alsancak Y, Unlu S, Elbeg S, et al. The Relationship between Pre-Infarction Angina and Serum Sphingosine-1- Phosphate Levels. Acta Cardiol Sin. 2014;30(6):546-52. 40. Cho YW, Jang JS, JinHY, Seo JS, Yang TH, KimDK, et al. Relationship between symptom-onset-to-balloon time and long-term mortality in patients with acute myocardial infarction treated with drug-eluting stents. J Cardiol. 2011;58(2):143-50. 39